Naringin, for example, reduces plaque progression once it decreases non-high-density lipoprotein cholesterol concentrations and biomarkers of endothelial dysfunction and inhibits the expression of ICAM-1 in endothelial cells, preventing immune cell adhesion and infiltration in the vascular wall (Choe et al., 2001; Chanet et al., 2012). This evidence concerns the gene ICAM1 and endothelial dysfunction.